Galera Therapeutics Inc. presented a supplemental net treatment benefit analysis of phase III ROMAN results at the 10th European Congress on Head and Neck Oncology, which took place March 8-11.
To access this subscriber-only content please log in or renew your subscription.
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe
Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.
Login Subscribe